Translational Health Sciences, Bristol Medical School, University of Bristol, United Kingdom; North Bristol NHS Trust, Bristol, United Kingdom.
North Bristol NHS Trust, Bristol, United Kingdom.
J Diabetes Complications. 2024 Nov;38(11):108865. doi: 10.1016/j.jdiacomp.2024.108865. Epub 2024 Sep 18.
A quarter of people with diabetes develop foot ulcer in their lifetime and are six times more likely to require a major lower limb amputation compared to the general population. Risk stratification tools can reliably identify those at the highest risk of ulceration, but it remains unclear if screening for foot complications can prevent limb loss in people with diabetes.
The aim of this systematic review was to determine whether population-based foot screening in people with diabetes reduces lower limb complications as assessed by development of foot ulceration, minor and major lower limb amputations, hospitalisation, or death.
MEDLINE, Embase, Emcare and CINAHL databases were searched to identify randomised and non-randomised controlled trials and observational studies (cohort, case-control and cross-sectional surveys). The screening process, study quality assessment and data extraction were performed by two independent reviewers.
Following abstract screening and assessment for eligibility, five out of 10,771 identified studies were included in the analysis. Of these studies, one demonstrated 24 % reduction in development of new ulceration following introduction of screening. Major amputations decreased by between 17 and 96 % in three studies. Hospitalisation rates were contradictory, with one study showing doubling in hospital admissions and another one reduction by 33 %. One study demonstrated no impact of screening on minor or major amputation rates. None of the studies addressed the effect of foot screening on all-cause mortality.
The number and quality of studies to support population-based foot screening to prevent lower limb complications in people with diabetes is low. Current evidence suggests variable impact of screening on important clinical outcomes.
四分之一的糖尿病患者在其一生中会发展为足部溃疡,与普通人群相比,他们发生下肢主要截肢的风险高 6 倍。风险分层工具可以可靠地识别出溃疡风险最高的人群,但目前尚不清楚对足部并发症进行筛查是否可以预防糖尿病患者的肢体丧失。
本系统评价的目的是确定在糖尿病患者中进行基于人群的足部筛查是否可以降低足部溃疡、小截肢和大截肢、住院或死亡等下肢并发症的发生率。
通过 MEDLINE、Embase、Emcare 和 CINAHL 数据库检索随机对照试验和非随机对照试验以及观察性研究(队列研究、病例对照研究和横断面调查),以确定基于人群的足部筛查是否可以降低糖尿病患者的下肢并发症发生率。筛查过程、研究质量评估和数据提取由两名独立的审查员进行。
经过摘要筛选和资格评估,10771 项研究中有 5 项被纳入分析。其中一项研究表明,在引入筛查后,新溃疡的发生率降低了 24%。三项研究显示,大截肢的发生率降低了 17%至 96%。住院率存在矛盾,一项研究显示住院人数增加了一倍,另一项研究则减少了 33%。一项研究表明,筛查对小截肢或大截肢率没有影响。没有研究涉及足部筛查对全因死亡率的影响。
支持在糖尿病患者中进行基于人群的足部筛查以预防下肢并发症的研究数量和质量都很低。现有证据表明,筛查对重要临床结局的影响各不相同。